Frontlight ResearchEarly access
Ovarian cancer trials in Czechia
15 of 18 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Brno-Stred, Ostrava, Prague
- Age
- 18 years and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - Phase 3Taking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Brno-Stred, Hradec Králové, Ostrava, Prague
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - Phase 3Not yet taking people in CzechiaStudy to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
- Where
- Brno-Stred, Hradec Králové, Nový Jičín, Olomouc, Ostrava, Prague
- Age
- 18 years and over
- People
- 544 worldwide
- Run by
- Genmab
See details and how to joinNCT07225270 · EU 2025-522167-15-00 - Phase 3Not yet taking people in CzechiaA Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
- Where
- Brno-Stred, Hradec Králové, Olomouc, Prague
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07791732 · EU 2025-522715-41-00 - Phase 3Taking peopleA Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Where
- Brno, Nový Jiín, Olomouc, Prague, Zlín
- Age
- 18 years and over
- People
- 1,630 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00 - Phase 3Not yet taking people in CzechiaStudy to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
- Where
- Hradec Králové, Nový Jičín, Prague
- Age
- 18 years and over
- People
- 688 worldwide
- Run by
- Genmab
See details and how to joinNCT07564141 · EU 2025-524202-15-00 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Ostrava, Prague
- Age
- 18 years and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - Phase 2/3Active, not recruitingA Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Where
- Brno-Stred, Novy Hradec Kralove, Prague
- Age
- 18 years and over
- People
- 860 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00 - Phase 2Taking peopleA Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- Where
- Ostrava, Prague
- Age
- 18 years and over
- People
- 640 worldwide
- Run by
- North Eastern German Society of Gynaecological Oncology
See details and how to joinNCT05460000 · EU 2022-502559-69-01 - Phase 2Taking peopleA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Where
- Brno-Stred, Hradec Králové, Ostrava, Prague
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AbbVie
See details and how to joinNCT07059845 · EU 2025-521606-18-00 - No phaseTaking peopleCanRisk-Based Ovarian Cancer Risk Assessment Versus Standard Practice (DISARM CSA)
- Where
- Prague
- Age
- 18 years to 75 years
- People
- 2,130 worldwide
- Run by
- Instituto Portugues Oncologia de Lisboa Francisco Gentil
See details and how to joinNCT07809659 - Phase 3Taking peoplePrehabilitation in Gynaecological Cancer Patients
- Where
- Prague
- Age
- 18 years to 85 years
- People
- 64
- Run by
- Charles University, Czech Republic
See details and how to joinNCT04789694 - Phase 3Not yet taking people in CzechiaAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Brno-Stred, Hradec Králové, Nový Jičín, Olomouc, Prague
- Age
- 18 years and over
- People
- 1,100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - Phase 2SuspendedCATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Where
- Nový Jičín, Ostrava, Prague
- Age
- 18 years and over
- People
- 230 worldwide
- Run by
- TORL Biotherapeutics, LLC
See details and how to joinNCT06690775 · EU 2024-517190-24-00 - Phase 3Not yet taking people in CzechiaNiraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
- Where
- Brno, Prague
- Age
- 18 years and over
- People
- 970 worldwide
- Run by
- AGO Study Group
See details and how to joinNCT05009082 · EU 2024-516066-11-00